JNJ-64407564, RoActemra 20 mg/mL concentrate for solution for infusion, JNJ-64407564, JNJ-64407564, Tyenne 20 mg/ml concentrate for solution for infusion, RoActemra 20 mg/mL concentrate for solution for infusion, Tyenne 20 mg/ml concentrate for solution for infusion, JNJ-64407564
64407564MMY1001
Phase 2 small_molecule active
Quick answer
JNJ-64407564, RoActemra 20 mg/mL concentrate for solution for infusion, JNJ-64407564, JNJ-64407564, Tyenne 20 mg/ml concentrate for solution for infusion, RoActemra 20 mg/mL concentrate for solution for infusion, Tyenne 20 mg/ml concentrate for solution for infusion, JNJ-64407564 for Multiple myeloma is a Phase 2 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- Multiple myeloma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active